Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.